ALPPS与常规二步肝切除在晚期结直肠癌肝转移中的随机对照研究
斯堪的纳维亚多中心RCT(LIGRO)纳入97例未来残肝体积比<30%的结直肠癌肝转移患者,比较ALPPS与二步肝切除的切除率。ALPPS组完成两阶段治疗的比例为92%,显著高于TSH组的57%,两组并发症、90天死亡率和R0切除率无显著差异。
要点
- 对于残肝体积不足的结直肠癌肝转移患者,ALPPS可显著提高完成两阶段治疗的切除率
- ALPPS与TSH在严重并发症、90天死亡率和R0切除率方面无显著差异
- TSH失败患者中部分可成功转为ALPPS治疗
核心结论
- 在结直肠癌肝转移且标准化未来残肝体积比<30%的患者中,ALPPS完成两阶段治疗的切除率优于TSH,且手术切缘、并发症和短期死亡率相当。
研究设计与样本
- 前瞻性多中心随机对照试验(LIGRO),2014年6月至2016年8月纳入97例结直肠癌肝转移且标准化未来残肝体积比<30%的患者。
主要发现
- ALPPS组切除率为92%(95%CI 84%-100%,44/48),TSH组为57%(95%CI 43%-72%,28/49),率比8.25(95%CI 2.6-26.6),P<0.0001。
- Clavien-Dindo≥3a并发症发生率ALPPS组43%(19/44)与TSH组43%(12/28)无差异,率比1.01(95%CI 0.4-2.6),P=0.99。
- 90天死亡率ALPPS组8.3%(4/48)与TSH组6.1%(3/49)无差异,率比1.39(95%CI 0.3-6.6),P=0.68。
- R0切除率ALPPS组77%(34/44)与TSH组57%(16/28)无显著差异,率比2.55(95%CI 0.9-7.1),P=0.11。
- TSH组中未能达到标准化未来残肝体积比30%的患者有12例成功接受ALPPS治疗。
临床怎么用
- 对于标准化未来残肝体积比<30%的结直肠癌肝转移患者,ALPPS可作为提高两阶段治疗完成率的策略,但需权衡两阶段手术的总体风险。
局限性
- 样本量较小(97例),可能不足以检测并发症、死亡率或R0切除率的细小差异。
- 基线特征除体重指数外组间无差异,但未报告其他潜在混杂因素的详细调整分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the study was to evaluate if associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) could increase resection rates (RRs) compared with two-stage hepatectomy (TSH) in a randomized controlled trial (RCT). BACKGROUND: Radical liver metastasis resection offers the only chance of a cure for patients with metastatic colorectal cancer. Patients with colorectal liver metastasis (CRLM) and an insufficient future liver remnant (FLR) volume are traditionally treated with chemotherapy with portal vein embolization or ligation followed by hepatectomy (TSH). This treatment sometimes fails due to insufficient liver growth or tumor progression. METHODS: A prospective, multicenter RCT was conducted between June 2014 and August 2016. It included 97 patients with CRLM and a standardized FLR (sFLR) of less than 30%. Primary outcome-RRs were measured as the percentages of patients completing both stages of the treatment. Secondary outcomes were complications, radicality, and 90-day mortality measured from the final intervention. RESULTS: Baseline characteristics, besides body mass index, did not differ between the groups. The RR was 92% [95% confidence interval (CI) 84%-100%] (44/48) in the ALPPS arm compared with 57% (95% CI 43%-72%) (28/49) in the TSH arm [rate ratio 8.25 (95% CI 2.6-26.6); P < 0.0001]. No differences in complications (Clavien-Dindo ≥3a) [43% (19/44) vs 43% (12/28)] [1.01 (95% CI 0.4-2.6); P = 0.99], 90-day mortality [8.3% (4/48) vs 6.1% (3/49)] [1.39 [95% CI 0.3-6.6]; P = 0.68] or R0 RRs [77% (34/44) vs 57% (16/28)] [2.55 [95% CI 0.9-7.1]; P = 0.11)] were observed. Of the patients in the TSH arm that failed to reach an sFLR of 30%, 12 were successfully treated with ALPPS. CONCLUSION: ALPPS is superior to TSH in terms of RR, with comparable surgical margins, complications, and short-term mortality.
引用
- Sandström P, Røsok BI, Sparrelid E, et al. ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial). Ann Surg. 2018. PMID: 28902669. doi:10.1097/SLA.0000000000002511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。